B7-H6:CD20

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameB7-H6:CD20
Drug Alias Nameanti-NKp30/anti-CD20 bispecific NK-cell engager (Christian-Albrechts-University Kiel/Genmab)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionNatural killer cell p30-related protein agonistsB-lymphocyte antigen CD20 modulators
TargetsNatural killer cell p30-related proteinB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmarkGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesChristian-Albrechts-University of Kiel
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenmab A/SChristian-Albrechts-University of Kiel
Active IndicationsN/A
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A